ISSN: 2304-3865

Journal Home

Journal Guideline

Chinese Clinical Oncology Q2 Unclaimed

AME Publishing Company Hong Kong

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Chinese Clinical Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 36. It has an SJR impact factor of 0,69 and it has a best quartile of Q2. It has an SJR impact factor of 0,69.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q2) Oncology (Q3)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,69

SJR Impact factor

36

H Index

70

Total Docs (Last Year)

198

Total Docs (3 years)

3129

Total Refs

384

Total Cites (3 years)

156

Citable Docs (3 years)

1.49

Cites/Doc (2 years)

44.7

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Clinical Rheumatology Q2
Pharmacological Reports Q2
Journal of Human Nutrition and Dietetics Q2
Diseases of the Colon and Rectum Q2
Oncology Reports Q2

Compare this journals

Aims and Scope

Best articles by citations

Preoperative radiotherapy in soft tissue sarcoma: from general guidelines to personalized medicine

Re-irradiation with stereotactic body radiation therapy (SBRT)

Surgical management of esophageal cancer

The role of Advanced Practice Providers in interdisciplinary oncology care in the United States

Perineural invasion in oral cancer: challenges, controversies and clinical impact

Cancer immunotherapy - the end of the beginning

Next frontiers in systemic therapy for soft tissue sarcoma

That's how you make drugs!

Chimeric antigen receptor (CAR) T and other T cell strategies for pancreas adenocarcinoma

An overview of modern proton therapy

What is the role of immunotherapy in breast cancer?

Moving forward: CCO is indexed in Emerging Sources Citation Index

SHOW MORE ARTICLES

Comparison of short-term outcomes between laparoscopic-assisted and open complete mesocolic excision (CME) for the treatment of transverse colon cancer

The way to precision medicine of our team

More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine

Surgical management of retroperitoneal sarcoma and opportunities for global collaboration

Rational combination of immunotherapy for triple negative breast cancer treatment

Gentle skin care guidelines for patients with mycosis fungoides

Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria

Cost-comparativeness of proton versus photon therapy

Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer

Low grade glioma: a journey towards a cure

SETDB1 is a new promising target in HCC therapy

Preface: pancreas adenocarcinoma